Know Cancer

or
forgot password

Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)


N/A
20 Years
90 Years
Open (Enrolling)
Both
Non-small Cell Lung Cancer (NSCLC)

Thank you

Trial Information

Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)


The ALK Break Apart FISH test detects chromosomal aberrations via fluorescence in situ
hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer
(NSCLC) tissue specimens. The FDA approved ALK kit is designed to detect rearrangements
involving the ALK gene (2p23). Results from the ALK Kit are intended for use, in conjunction
with and not in lieu of current standard diagnostic procedures, as an aid for the
pathologist in the identification of patients eligible for treatment with XALKORI®
(crizotinib).


Inclusion Criteria:



- Well stained slides with bright FISH signals

Exclusion Criteria:

- Very old slides that were already bleached

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Authority:

United States: Institutional Review Board

Study ID:

ASI-ALK-F

NCT ID:

NCT01620853

Start Date:

May 2012

Completion Date:

Related Keywords:

  • Non-Small Cell Lung Cancer (NSCLC)
  • Non-small cell lung cancer (NSCLC)
  • ALK probe
  • FISH
  • Chromosomal aberrations
  • Carcinoma, Non-Small-Cell Lung
  • Chromosome Aberrations
  • Chromosome Disorders
  • Lung Neoplasms

Name

Location

Scott & White Hospital,Temple,, Texas